Antiviral agents for the prevention of the sexual transmission of herpes simplex in discordant couples

Current Opinion in Infectious Diseases

Volumn 17, Issue 1, 2004, Pages 45-48

  Patel, Raj ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acyclovir; Genital herpes; Herpes simplex virus; Transmission; Valaciclovir

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

CLINICAL PRACTICE; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; PROPHYLAXIS; REVIEW; RISK FACTOR; RISK REDUCTION; SEXUAL TRANSMISSION; DISEASE TRANSMISSION; FEMALE; HERPES SIMPLEX; MALE; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HERPES SIMPLEX; HUMANS; MALE; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES;

EID: 3042827083     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200402000-00009     Document Type: Review

References (21)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
2. Becker TM, Biount JH, Guinan ME. Genital herpes infections in private practice in the United States, 1966 to 1981. JAMA 1985; 253:1601-1603.
3. National Center for HIV, STD and TB Prevention. Sexually transmitted surveillance, 1996. Atlanta, GA: Centers for Disease control and Prevention; September 1997.
4. Pass R, Weber T, Whitley RJ. Herpesvirus infections in pregnancy. PAREXEL MMS Europe Ltd.; 2000.
5. Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. J Clin Virol 2002; 24:183-192. This study confirms the importance of HSV as a cause of genital ulceration in developing countries.
6. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52. This meta-analysis reviews the epidemiological data for the association of HSV-2 infection and HIV. The extended discussion around trial quality, site and the different types of infection make this a valuable paper.
7. Wald A, Baseman J, Selkes, et al. Sexual transmission of genital herpes simplex virus (HSV): a time-to-event analysis of risk factors associated with rapid acquisition. In: National STD Prevention Conference, Milwaukee, Oregon, 2000.
8. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-340.
9. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280:1161-1167.
10. Gottlieb SL, Douglas JM Jr, Schmid DS, et al., and the Project RESPECT Study Group. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J Infect Dis 2002; 186:1381-1389. The authors demonstrate the limited impact that intensive counselling may have on the behavioural risk factors for HSV acquisition.
11. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-3106.
12. Wald A, Langenberg A, Kexel E, et al. Condoms protect men and women against herpes simplex virus type 2 (HSV-2) acquisition. In: National STI Prevention Conference. 2002. San Diego [Abstract B9E].
13. Rana RK, Paavonen J, Tyring S, et al. Demographic factors, behaviour and knowledge associated with HSV-2 infection in individuals whose partners have genital herpes. Paris: Eurogen; 2003.
14. Patel R, Sacks S, Tyring S, et al., on behalf of the Valaciclovir HSV Transmission Study Group. Once daily valaciclovir reduces transmission of genital herpes. Paris: Eurogen; 2003.
15. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
16. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998; 178:603-610.
17. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998; 280:887-892.
18. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997; 99:1092-1097.
19. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45 (Suppl. T3):1-8.
20. Sacks SL. Improving the management of genital herpes. Hosp Pract 1999; 34:41-49.
21. Corey L, Tyring S, Beutner K, et al. Once daily valaciclovir reduces transmission of genital herpes. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 27-30 September 2002 [Abstract LB-3].